AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This study is a phase I/II study to determine the safety and efficacy of AMD3100 when
combined with mitoxantrone, etoposide, and cytarabine in patients with relapsed or refractory
AML.
We hypothesize that disrupting the interaction between AML blasts and the marrow
microenvironment with AMD3100 may enhance the cytotoxic effect of chemotherapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Treatments:
Cytarabine Etoposide Etoposide phosphate JM 3100 Mitoxantrone Plerixafor